Intravesical Mitomycin C Instillation as a Prophylactic Treatment of Superficial Bladder Cancer.
- Author:
Hyeon Hoe KIM
1
;
Chong Wook LEE
Author Information
1. Department of Urology, College of Medicine, Seoul National University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
intravesical chemotherapy;
mitomycin C
- MeSH:
Follow-Up Studies;
Humans;
Mitomycin*;
Recurrence;
Urinary Bladder Neoplasms*;
Urinary Bladder*
- From:Korean Journal of Urology
1987;28(2):209-214
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Twenty one patients with multiple, large or recurrent superficial bladder cancer were treated with intravesical Mitomycin C instillation after TUR, and another 22 patients were treated with TUR alone The Mitomycin C group and control group were statistically identical in tumor size, grade, multiplicity and recurrences. Mean follow-up period were 13.9 months in Mitomycin C group and 23.2 months in controls. Recurrence rate was 42.9% in Mitomycin C group, and 40.9% in controls during the first 3 months and it was 66.7% and 68.2% respectively during the 12 months. Recurrences per 100 patient months was lO.1 and 9.6 respectively and the interval between the treatment and the first recurrence was 6.69 and 7.28 months respectively. Two of 21 patients in Mitomycin C group and 4 of 22 patients in controls had recurrent tumors with progression in stage during the follow-up period. There was no significant difference between the 2 groups. Therefore we can conclude that intravesical Mitomycin C instillation is not effective in the prophylaxis of tumor recurrence in the special group of patients with high risk of recurrence. This result is contrary to the several reports indicating marked reduction of recurrence by Mitomycin C. We discussed some factors which might influence to the 2 different outcome.
